jRCT2080222696未知3 期
A phase III long-term study of HP-3000 in patients with Parkinson's disease
适应症
试验速览
- 阶段
- 3 期
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, open-label, single group assignment
入排标准
- 年龄范围
- 20age old over 至 79age old under（—）
- 性别
- All
入选标准
- •Patients diagnosed with Parkinson's disease in stages 1 to 4 on the modified Hoehn & Yahr scale.
排除标准
- •Patients with history of hypersensitivity to ropinirole.
- •Patients with severe hepatic dysfunction.
- •Patients who have cutaneous abnormality at planned application site that can be worsen by application with investigational product.
结局指标
主要结局
-
Safety, and efficacy.
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
ong-term study of HP-3000 in patients with Parkinson's diseaseParkinson's diseaseJPRN-jRCT2080222696Hisamitsu Pharmaceutical Co.,Inc.
未知
3 期
ong-term study of HP-3060Perennial allergic rhinitisJPRN-jRCT2080222924Hisamitsu Pharmaceutical Co., Inc.
未知
2 期
Phase II clinical study in patients with Parkinson's disease.Parkinson's diseaseJPRN-jRCT2080221631Hisamitsu Pharmaceutical Co., Inc.
未知
2 期
Phase 2/3 clinical study of HP-3150 in patients with cancer pain.Cancer painJPRN-jRCT2080222905Hisamitsu Pharmaceutical Co., Inc
未知
3 期
Phase 2/3 clinical study of HP-3150 in patients with cancer pain.jRCT2080222905Hisamitsu Pharmaceutical Co., Inc